
ãæåèµ·ããã2023.9.14 Phillip Buckhaultså士ã«ããã³ããã¯ã¯ãã³DNAæ±æåé¡ã«ã€ããŠã®èšŒèšïŒãµãŠã¹ã«ãã©ã€ãå·äžé¢å»äºç¹å¥å§å¡äŒã«ãŠïŒ
ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒ
ãã®èšäºã¯ãåç»ã«æ¥æ¬èªåå¹ãä»äžããã
tonakaiããïŒ@tonakai79780674ïŒãååã®å
å广
å ±ã«ç·šéãšæŽçãå ãããã®ã§ã
ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒ
æåèµ·ããã«ããã£ãŠ
äœå人ã«ãæ¥çš®ãããmRNAã¯ã¯ãã³ã
ãããŸã§äœåºŠããããã¿ã€ãã³ã°ãéããŠããïŒâ»ïŒã
ä»ããããã®ã¿ã€ãã³ã°ãåãæ»ãæã
å士ã®è¡æçãªèšŒèšããå®ç®ããã
â» åè
æäžåº·æææïŒ
ã2021幎ã®å§ãã®æ®µéã§ã¹ãã€ã¯ã¯ææ¯ã ã£ãŠããšã¯åãã£ãŠãããã§ãããããããã§ãããããšæãã°ããããããã§ããã
ãããšãªãã¯ãã³åãåºãã£ããããªãã§ããããªãã¯ãã³åã¯èºçã«ãªãã¥ãããšããããšã ã£ãã®ã§ããããææããã»ããè¯ãã£ããããããªãã£ãŠããè°è«ããã£ãããã§ããããããã§ããããããå¯èœæ§ããã£ããã§ãããã
ãããã²ãšã€ã®ã¿ã€ãã³ã°ã¯ãmRNAã¯ã¯ãã³ã«çžåœéã®DNAãæ··ãã£ãŠãããšããæ®µéã§ããããããå¯èœæ§ããã£ããã§ãã
ãããããã¿ã€ãã³ã°ãéããŠããã§ãã
ãæ°åã³ããXBBå察å¿ã¯ã¯ãã³ãæã£ãŠã¯ãããªãïŒ
ãã¡ã€ã¶ãŒå®éšããŒã¿ã®"ããªãã¯"ãæŽãã
åç»ïŒãªãªãžãã«ïŒ
åç»ïŒæ¥æ¬èªåå¹ããïŒ
Phillip Buckhaultså士ããmRNA COVIDã¯ã¯ãã³ã«æ€åºãããDNAæ±æã«ã€ããŠäžé¢ã§èšŒèš
â tonakai (@tonakai79780674) September 18, 2023
翻蚳ã¬ãã¥ãŒã¯æå°éã§ãã https://t.co/NTjAqWSJCw pic.twitter.com/8WFfISpEBo
å šæ
00:00ãèªå·±ç޹ä»
ç§ãç¥ããªãæ¹ãžãç§ã®ååã¯ãã£ãªããã»ããã¯ãã«ãã§ããçååŠãšååçç©åŠã®å士å·ãæã£ãŠããŸããããéºäŒåã®å°éå®¶ã§ãåºæ¬çã«ã¯ãµãŠã¹ã«ãã©ã€ã倧åŠã§ããã®éºäŒåç ç©¶ãããŠããŸããã€ãŸããç§ã¯äººéã®ã²ãã ãäžçã®éã«ã©ã®ããã«å€ç°ãããããããŠããã®ãã¡ã©ãããããåŒãèµ·ããã®ãã«ã€ããŠã®å°éå®¶ã§ããæè¡çã«ã¯ãDNAã·ãŒã±ã³ã¹ã®æè¡ã«éåžžã«é·ããŠãããšããããšã§ããç§ã¯æ¢ããŠãããã®ãç¥ããªããŠãããã®ã·ãŒã±ã³ã¹ãè§£èªã§ããŸãããããŠããç§ããšèšã£ãŠããæããç§ã®ç 究宀ã®ã¡ã³ããŒããæããŠããŸãã圌ãã®ååãèãããšã¯ã§ããŸããããçŽ æŽãããä»äºãããŠãã人ã ãããŸãã
ç§ãã¡ã¯ãæ¬æ¥ååšããŠããªãå Žæã§ã®ç°è³ªãªDNAæçããéåžžã«äœãæ¿åºŠã§ãã£ãŠãæ€åºããããšã«ãæ¬åœã«é·ããŠããŸãããã³ãããã¯äžãç§ãã¡ã¯ãã®ã¹ãã«ãå©çšããŠãå€ãã®æ¹ãè¡ã£ãåŸæ¶²æ€æ»ã«ããCOVIDæ€æ»ãçºæããŸãããããã¯ç§ã®ç 究宀ããçãŸãããã®ã§ãã
å士ã®ç 究宀ã¯ãã³ããã®åŸæ¶²æ€æ»æ¹æ³ãéçºããã
ç§ãã¡ã¯ãã®ãããªããšã«éåžžã«é·ããŠããŸããããã®ãããç§ã¯ãµãŠã¹ã«ãã©ã€ãå·ããã®çµç¹ã§ããªãã®å°æ¬ãåŸãŠããŸãããªããªãã人ã ãæããŠããçå€äžã«å€§éã®COVIDæ€æ»ãè¡ãã圌ãã«ãããããããªãã®å®¶ã«ã¯COVIDã¯ãããŸããããšäŒãããããã¯ãããããŸãããšäŒãããããããã§ãããããã£ãŠãç§ãããã«ã³ã¡ã³ãããããã®è³æ Œã¯ãæè¡çãªãã®ãšãµãŠã¹ã«ãã©ã€ãå·ã®é¢ä¿æ§ã®äž¡æ¹ããããŸããããã§ã¯éåžžã«çãããŒãã«çµããŸãããããã«ã¯å€ãã®èŠå¶äžã®åé¡ãé¢ä¿ããŠããŸããããæãã®ã§ããã°ããããã詳ãã説æããã®ã¯ãã¡ãã«ä»»ããŸããèŠå¶åœå±ã®ç£èŠãæ¹åãããå¯èœæ§ã®ããå Žæã®äºäŸãšããŠãPfizerã¯ã¯ãã³ã®äžéšã®åé¡ã«ã€ããŠçãç¯å²ã§ã話ãããããŸããã
ãŸãæåã«ãæç®ã®è§£éãšããŠãPfizerã¯ã¯ãã³ã¯äººã ãæ»ããå®ãã®ã«ããªãäžæããã£ããšèšããŸããããã³ãããã¯ã®æ¡å€§ãæ¢ããã®ã«ã¯ã²ã©ãçµæã§ããã
ã¯ã¯ãã³ã¯æææ¡å€§ãæ¢ããããªãã£ãã
åæã®è³æã§ã¯ææã鲿¢ã§ããããšã瀺ãããŸããããããã¯1ãæçšåºŠããç¶ããŸããã§ãããæç®ã®å°éçãªè©äŸ¡ã«ããã°ãPfizerã¯ã¯ãã³ã¯äººã ãå¢å Žããé ãããã®ã«ããªãããŸããããŸãããããã³ãããã¯ã®æ¡å€§ãæ¢ããã®ã«ã¯ã²ã©ãçµæã§ãããããã¯ç§ãã¡ãæã£ãŠããææªã®éžæè¢ã®äžã§ã¯æè¯ã®ãã®ã§ãããããã§ããããã¯ã»ãšãã©åæã§å±éããããšç§ã¯ãŸã ä¿¡ããŠããŸãããç«äºãèµ·ããŠãããããå€ãã®è¿éãåãããŸãããæ¬¡åã¯ããã§åŠãã æèšããããè¯ãä»äºãããããšãã§ããã§ãããã
ããã¯ç§å人ã®èŠè§£ã§ãããç§ã®å²åŠçãªèãæ¹ã¯ãçãããèããããšãããã§ãããããªãã«ã ã®ååã«åºã¥ããŠããŸããæãã·ã³ãã«ãªèª¬æãéžã³ãŸããããã«ã¯ããäžã€ããã³ãã³ã®ååãšãããã®ããããŸããããã¯ãèœåäžè¶³ã«ãã£ãŠãããã説æã§ãããã®ã«æªæãåž°ããã«æžãããšãããã®ã§ããã§ãã®ã§ãç§ã¯ãã®ç¶æ³ã§å¯å€§ã§ãããããšæã£ãŠããŸããæœåšçã«ã¯æªæããããããããŸããããç§ã¯ãã åãªãèœåäžè¶³ãšå¯å€§ã«è§£éããããšããŠããŸãã
æªæã¯çœ®ããŠããããèœåäžè¶³ãšçè§£ãããã
03:40ãDNAãé節ãªå¯äœçšã®åå ã

Pfizerã¯ã¯ãã³ã¯ãã©ã¹ããDNAã§æ±æãããŠããŸããããã¯åãªãmRNAã ãã§ã¯ãããŸãããããã«ã¯DNAã®æçãå«ãŸããŠããŸãããã®DNAã¯ãmRNAãäœæããéã«in vitro転ååå¿ã®ãã³ãã¬ãŒããšããŠäœ¿çšãããDNAãã¯ã¿ãŒã§ããç§èªèº«ã®ç 究宀ã§ã·ãŒã±ã³ã¹ãè¡ã£ããããããã¯äºå®ã§ãããšç¥ã£ãŠããŸãã
ã¯ã¯ãã³ãDNAæçã§æ±æãããŠããã®ã¯äºå®ã ã
ã³ãã³ãã¢ã§é åžãããPfizerã¯ã¯ãã³ã®ãã€ã¢ã«ã«ã€ããŠãç§ã®ååã®äžäººãè¬åŠéšã®äºé²æ¥çš®ããã°ã©ã ãæ åœããŠããŸãããç§ã¯ãã®çç±ãåãããªããã圌ã¯å šãŠã®ãã€ã¢ã«ãä¿ç®¡ããŠããŸããã圌ã®å·å庫ã¯ã空ã®ãã€ã¢ã«ã§ãã£ã±ãã§ãããããŠã空ã®ãã€ã¢ã«ã«ã¯å°ãã ãåºã«æ®ã£ãŠããŸãã圌ã¯ãã¹ãŠç§ã«æž¡ããç§ã¯ããããèŠãŸãããããã§ã³ãã³ãã¢ã§ã®2ã€ã®ããããé åžãããŸãããç§ã¯ãããã®2ã€ã®ãããã確èªããã·ãŒã±ã³ã¹ã§ç¢ºèªããŸãããç§ã¯ã¯ã¯ãã³ã«å«ãŸããŠãããã¹ãŠã®DNAãã·ãŒã±ã³ã¹ããäžèº«ã確èªã§ããŸãããããŠãããã«DNAãããããšã«é©ããŸããããããäœã§ãããã©ããã£ãŠããã«å ¥ã£ãã®ããããçšåºŠæšæž¬ã§ããŸãããããŠãããã«ãã人éã®å¥åº·ãšçç©åŠã®äž¡æ¹ã«åœ±é¿ãäžããå¯èœæ§ã«ã€ããŠãç§ã¯ããçš®ã®èŠæå¿ãæ±ããŠããŸããããããå¯èœã«ããèŠå¶ããã»ã¹ã«ã€ããŠãèŠæå¿ãæ±ãã¹ãã§ãã
ãããã£ãŠãç§ã®èŠè§£ã§ã¯ããã®DNAã¯ãå¿åæ¢ã«ããæ»äº¡ãªã©ããŸãã§ã¯ãããŸããé節ãªå¯äœçšã®åå ãšãªãå¯èœæ§ããããŸããçŸåšãã¯ã¯ãã³æ¥çš®åŸã«æªããæ»äº¡ããã人ã ã®ã±ãŒã¹ãå€ãå ±åãããŠããŸãããããäœãåŒãèµ·ãããã®ãã蚌æããã®ã¯é£ããã§ããããã¯äžæçã«é¢é£ããŠããã ãã§ãããããŠããã®DNAã¯åŠ¥åœãªã¡ã«ããºã ã§ãã
æ¥çš®åŸã®å¯äœçšã»æ»äº¡ã¯ãDNAæ±æãåå ãããããªãã
ãã®DNAã¯ãã¯ã¯ãã³ã®æåã§ãã©ã³ã¹ãã§ã¯ã·ã§ã³ïŒéºäŒåå°å ¥ïŒãåãã现èã®ã²ãã DNAã«çµã¿èŸŒãŸããå¯èœæ§ããããŸããããã¯ãã ã®ä»çµã¿ã§ããç§ãã¡ã¯åžžã«ç 究宀ã§ãããè¡ã£ãŠããŸããDNAã®æçãåãããããPfizerã¯ã¯ãã³ã®ãããªè質è€åäœãšæ··ããŸããããã现èã«æ³šããããã®å€ãã现èå ã«åã蟌ãŸããDNAã«åã蟌ãŸããããã现èã®æ°žä¹ çãªäžéšã«ãªããŸããããã¯äžæçãªãã®ã§ã¯ãããŸãããããã¯ãã®çްèããã³ãã®åå«ã®ãã¹ãŠã«ãšã£ãŠãããããæ°žé ã«ååšãããã®ã§ããã ãããç§ã¯ãã®ã¯ã¯ãã³ã«ãã®DNAãå«ãŸããŠããããšã«ã€ããŠãå°ãå¿é ããŠããŸããããã¯RNAãšã¯ç°ãªããæ°žç¶çãªãã®ã«ãªãå¯èœæ§ãããããã§ãã
DNAæçã¯æ¥çš®è ã®ã²ãã DNAã«çµã¿èŸŒãŸãããã®åå«ã圱é¿ãåãããããããªãã
ããã¯ã幹现èã®ãããªé·å¯¿åœã®äœçްèã®ã²ãã ä¿®æ£ã«ãããå®éã®ãªã¹ã¯ã§ãããçè«çã«ã¯ãããã¯ãã¹ãŠçè«çãªæžå¿µã§ãããåäœååçç©åŠã«åºã¥ããŠããªãåççãªãã®ã§ãããããããã®çµç¹ãžã®æç¶çãªèªå·±å ç«æ»æãåŒãèµ·ããå¯èœæ§ããããŸãã
ãŸãããã®å€æ¥ã®DNAãã²ãã å ã®ã©ãã«çå°ãããã«ãã£ãŠãå°æ¥çãªããã®éåžžã«çŸå®çãªçè«çãªã¹ã¯ããããŸããããã¯è «çæå¶éºäŒåã劚ããããçéºäŒåãæŽ»æ§åããããããå¯èœæ§ããããŸããçããã±ãŒã¹ã ãšæããŸããããªã¹ã¯ã¯ãŒãã§ã¯ãªããšæããŸãã
DNAæçã®çµã¿èŸŒãŸãæ¹ã«ãã£ãŠã¯ãããåã®å¯èœæ§ãããã
ãããèµ·ãã£ãŠããã®ãã©ãããèŠæ¥µããå¿ èŠããããããããŸããããããŠãå床èšããŸãããèªå·±å ç«ã¯ç§ã®å°éå€ã§ããå ç«åŠè ã§ã¯ãããŸããããããã®ãªã¹ã¯ã«ã€ããŠã¯è©³ããã§ãããããç§ã®åŸæåéã§ãããã®ããšã¯åãã£ãŠããŸãããå¯èœæ§ããããŸãã
06:40ãDNAãšRNA

ããŠãå°ãããã¢ãã¯ãªç§åŠã§ãããååçç©åŠã®äžå¿åçã¯ãDNAãRNAã«è»¢åããããšããããšã§ããããããŠãRNAã¯ã¿ã³ãã¯è³ªã«ç¿»èš³ãããŸãããããçåœã®æµãã§ãããªããããéèŠãªã®ããšèšããšãããã§ã®è°è«ãšããŠã¯ãDNAã¯é·æçãªæ å ±ã®ä¿åè£ çœ®ãªã®ã§ããããªããçãŸããæã®DNAã¯ãããªãã亡ããªããŸã§æã¡ç¶ããåäŸãã¡ã«åãç¶ãããŸããDNAã¯äœåäžå¹Žãæç¶ããåäŸãã¡ã«åãç¶ãããšãã§ããã°ãäžä»£ãè¶ ããŠç¶ãããšããããŸããããã§ããããDNAã®å€åã¯æ®ããŸãã
RNAã¯ãã®æ§è³ªäžãäžæçãªãã®ã§ããRNAã¯æç¶ããŸããããã¯ã¯ãã³ã®è²©å£²ã®éã«ã¯ãã®ç¹åŸŽãã¢ããŒã«ãããŸãããã·ã¥ãŒããŠãªãžã³ã¯RNAã®æç¶æéãå°ãé·ãããããšãäºæ³ãããŸããããããã§ãäžæçãªçŸè±¡ã§ããããã¯æ°æéããæ°æ¥æç¶ããããšããããŸããã¿ã³ãã¯è³ªã¯äœãããåŸãæ°žé ã«ã¯æç¶ããŸããããããã¯æ°æéããæ°æ¥æç¶ããŸããããããDNAã«å ¥ã蟌ãã ãã®ã¯ãé·ãéãããšãã°äžçç¶ãå¯èœæ§ããããŸãã
RNAã¯äžæçã ããDNAã¯æç¶ãããäžä»£ãè¶ ããŠç¶ãã
07:57ãDNAæçã®ãã现èãžã®åœ±é¿

ããã¯ãç§ãå®éšå®€ã§è¡ã£ãPfizerã¯ã¯ãã³ã®æ°ãããããã®ã·ãŒã±ã³ã¹ãªãŒããã·ãŒã±ã³ã¹ã©ã³ã®ç»åã§ããããã«ãã现ããç·ã¯ãã¯ã¯ãã³ã«å«ãŸããå°ããªDNAã®æçã§ãããããã¯è²©å£²æŠç¥ãããŒã±ãã£ã³ã°ãã£ã³ããŒã³ã®äžéšã§ã¯ãããŸããããååšããŠããŸãããããã¯ãããããããŸããããã«ãããã®å°ããªã°ã©ãã¯ããµã€ãºã®ååžã§ããããŒã¯ã¯çŽ100å¡©åºå¯Ÿã120å¡©åºå¯Ÿã§ããã¯ã¯ãã³ã«å«ãŸããDNAã®æçã¯ã100ã120ãšããçãå°ããªæçã§ããçŽ500å¡©åºå¯Ÿã®ãã®ããããæ°åã®ãã®ããããŸãããã»ãšãã©ã¯100å¡©åºå¯ŸçšåºŠã§ãã
ãªããããéèŠãªã®ã§ããããïŒãªããªããDNAã®æçãããã²ãã ã«çµã¿èŸŒãŸãã確çã¯ããã®ãµã€ãºãšã¯é¢ä¿ããªãããã§ããã²ãã ã®ãªã¹ã¯ã¯ãååšããç²åã®æ°ã«ãã£ãŠæ±ºãŸãã ãã§ããã€ãŸããã·ã§ããã¬ã³ãæŽæ¿¯æ¿ã«æã£ãå Žåãã¹ã©ãã°åŒŸïŒåçºåŒŸïŒã§ãããçšåºŠã®ç¢ºçã§åœãããŸãããããã¯ã·ã§ããïŒæ£åŒŸïŒã®æ¹ãåœãã確çãé«ããªããŸãããïŒã¯ã¯ãã³ã«å«ãŸãããããã®å°ããªDNAã®æçã¯ãããã¯ã·ã§ããã«é¡äŒŒããŠããŸããã¯ã¯ãã³æ¥çš®ãåãã人ã®çްèãæ¹å€ããããã«ãéåžžã«å€ãã®æ©äŒããããŸãã
倿°ã®DNAæçã®æ±æã¯ããŸãã§æ£åŒŸéã«ããæ»æã®ããã ã
æçã¯éåžžã«å°ããã§ãããªããªãããã®éçšã§ããããåãå»ãã§æé€ããããã§ãããå®éã«ã¯ã²ãã æ¹å€ã®å±éºæ§ãå¢å ããŸããããããä»ã«è³ãçµç·¯ã§ãã
DNAé€å»ã®ããã«åãå»ãã çµæããªã¹ã¯ãå¢å€§ããã
ç§ã®æèŠã§ã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ã ã®å¹¹çްèããDNAãµã³ãã«ãã·ãŒã±ã³ã¹ããŠããã®çè«äžã®ãªã¹ã¯ãèµ·ãã£ããã©ããã調ã¹ãã¹ãã§ããããã¯æ¬åœã«æ·±å»ãªç£èŠã®ãã¹ã ãšæããŸããé£éŠã¬ãã«ã§èµ·ãã£ãèŠå¶äžã®èŠèœãšãã§ããã誰ãããããã©ããã§å®çŸãããã¹ãã§ãã
ïŒããã¯ãã«ãå士ãããã¯å¯èœã§ããïŒïŒ
ã¯ããç§ãã¡ã¯ãã®ãããªããšãè¡ã£ãŠããŸãããå ¬è¡ã®ä¿¡é ŒãåŸãããã«ãå€ãã®äººã ã«ãã£ãŠè¡ãããå¿ èŠããããŸãã
ïŒäºè§£ã§ããåŸã§ããã«ã€ããŠããã«è©±ããŸããããïŒ
ã¯ããããã¯ç§ãã¡ã®ä»äºã§ããç§ã¯ãããé£éŠã¬ãã«ã§è¡ãããã¹ãã ã£ããšèããŠããŸãã
é£éŠã¬ãã«ã§æ¥çš®è ã調æ»ãã¹ãã
10:25ãDNAæ±æã®åå

ãããã®ãã¹ãŠã®DNAã®æçãååããããããã€ãªãåãããŠãå ã®DNAãã©ã®ãããªãã®ã ã£ãããåçŸããŸãããããã¯ãŸããç§ãã¡ãåžžã«å®éšå®€ã§è¡ã£ãŠããããšã§ããããã«ãããã¹ãŠã®å°ããªèµ€ãšç·ã®ç·ã¯ãããããç¬ç«ããå°ããªDNAã®æçã§ãããã®ã·ãŒã±ã³ã¹ã©ã³ã§ã¯ããããã10äžåã®DNAæçãå«ãŸããŠããã¯ãã§ãããããããã¹ãŠå ã«æ»ããŠãã©ãããæ¥ããããã®åãã確èªããããšãã§ããŸããããã¯Agilent瀟ãããªã³ã©ã€ã³ã§è³Œå ¥ã§ãããã©ã¹ããã§ãããããŠãæããã«Pfizerã¯ãã®ãã©ã¹ããã䜿çšããããã«ã¹ãã€ã¯ãã¯ããŒãã³ã°ããŸããããããŠã圌ãã¯ãããin vitro転å翻蚳ãšããããã»ã¹ã§äœ¿çšããŸããã
DNAæçãã€ãªãåãããçµæãAgilent瀟ã®ãã©ã¹ãããåçŸã§ããã
in vitro転åã§ã¯ãRNAããªã¡ã©ãŒãŒã«ãã®ãã©ã¹ãããäžãããšãããããã®mRNAã®ã³ããŒãäœãããŸãããã®mRNAãåãåºããŠãè質ããç²åã®ãã©ã³ã¹ãã§ã¯ã·ã§ã³è©Šè¬ãšæ··ãããšãmRNAã¯ã¯ãã³ãã§ããŸãããDNAãåãé€ãããšã«å€±æããŸããããããã£ãŠããããã®å°ããªæçã¯ãããã现åãã«ããããšããåªåã®çµæã§ãããã©ã¹ããã®ãããã®å°çã¯ãRNAãšäžç·ã«ããã±ãŒãžãããŸãããããã¯ãDNAã·ãŒã±ã³ã¹ã調ã¹ãããšã§æããã«ãªã£ãäºå®ã§ãã
DNAæçã¯ãé€å»ããããšçްåãã«ããçµæã
ããã§å°ãèŠå¶ã®æ³šæç¹ãè¿°ã¹ãŸããin vitro転ååå¿ã§RNA転åãè¡ãã«ã¯ãDNAãã³ãã¬ãŒããäžããå¿ èŠããããŸããRNAãäœãããã®æç€ºã ãã®åæDNAã®ãã³ãã¬ãŒããäžããããšãã§ããŸãããããŠããããç·æ¥äœ¿çšèš±å¯ãšèšåºè©Šéšã®ååŸã«äœ¿çšãããŸãããããã¯ããã»ã¹1ãšåŒã°ããŠããŸãããã®ãããªãã®ã調ã¹ããšããããŸãã圌ãã¯å¿ èŠãªéšåã ãã§PCRç£ç©ãäœããŸããããããŠãin vitro転åãè¡ããããããRNAãããããäœããŸããã詊éšã«äœ¿çšããããã®ã«ã¯ãã©ã¹ããDNAã®æ±æã¯ãããŸããã§ããããã ããPCRç£ç©ãäœãã ãã§ã¯ãå šäžçã«ã¯ã¯ãã³ãæ¥çš®ããããã«å¿ èŠãªã¹ã±ãŒã«ã«ã¯ãªããŸããã§ããããã®ããããã®ãã³ãã¬ãŒãã®çç£ãæ¡å€§ããããå®äŸ¡ãªæ¹æ³ã¯ãPCRç£ç©ããã®ãã©ã¹ãããã¯ã¿ãŒã«ã¯ããŒãã³ã°ãããã©ã¹ãããã¯ã¿ãŒã现èã«å ¥ãã倧ããªã¿ã³ã¯ã§çްèãå¢ããããšã§ãã圌ãã¯ããªãã®ããã«ããããã®ãã©ã¹ããDNAãäœããŸããããããããã®ãã©ã¹ããDNAããã³ãã¬ãŒããšããŠäœ¿çšããŠããã®è»¢ååå¿ãä¿é²ããŠRNAãäœããŸãããããŠãããã補é ãããã«æ±æç©è³ªãå ¥ãåå ãšãªããŸããããã ããèªå¯è©Šéšã«äœ¿çšããããã®ã«ã¯å«ãŸããŠããŸããã§ãããã¡ãã£ãšãªã¿ã¯ã£ãœãç§åŠãããããŸããããèŠå¶äžã®åœ±é¿ããããŸããã
詊éšçšã¯DNAæ±æãªããäŸçµŠçšã¯DNAæ±æããïŒå€§éçç£äžã«æ±æãããïŒã
13:05ãã¯ã¯ãã³1ååã«å«ãŸããDNAé


ç§ãã¡ã¯å®éšå®€ã§ãã®ç©è³ªã®éãç°¡åã«æž¬å®ã§ããŸããããããããšã¯åŸæã§ããããã¯åãã§ãããMITã®ååãäœã£ãå°ããªPCRãã¹ãã§ãã以åã¯MITã®Broad Instituteã§åããŠããŸããããããããã§ã¯ããŒã³ããŸãããããã¯ãåŸæ¶²æ€æ»ã§çãããè¡ã£ãPCRãã¹ããšäŒŒãŠããŸããåãã¢ã€ãã¢ãšåãå°éç¥èã䜿ã£ãŠããŸãããããŠãã¯ã¯ãã³ãä»ã®çµç¹ã«ãã®ç©è³ªãã©ãã ãå«ãŸããŠããããæ£ç¢ºã«éãããšãã§ããŸãã
ããã1åã®æäžã«ãããŠç§ãã¡ãæ¢ããŠãããã®1ã€ã®éšåãçŽ20ååååšãããšæšå®ããŠããŸããç§ããèŠãããããããèŠè¿ããŠã¿ãŠãã ãããç§ãã¡ãæ¢ããŠããå°ããªéšåã¯ãã¡ããã©ããã«ãããŸããããããããã20ååãããšããã°ãä»ã®éšåã¯ããã2000ååãããŸããã€ãŸããã¯ã¯ãã³ã®1åã®æäžã«ã¯ãããã2000ååã®ãã©ã¹ããDNAãå«ãŸããŠãããè質ããç²åã«å ãŸããŠããã®ã§ã现èå ã«éãå±ããæºåãã§ããŠãããã§ããã ããããŸããïŒããã¯è¯ããªãã¢ã€ãã¢ã§ãã
ã¯ã¯ãã³1ååã«2000ååã
ãããè質ããç²åã«å ãŸãã现èã«åã蟌ãŸããããç¶æ ã
14:30ãçµè« ãæ¥çš®è ã«æ®ã蚌æ ã

ãã®çµè«ãããã¯ã¯ãã³ãæ¥çš®ãã人ã ã®çµç¹ãµã³ãã«ã調ã¹ãã¹ãã§ããç¹ã«è¢«å®³ãåãã人ã ã«çŠç¹ãåœãŠããšè¯ãã§ãããããã¯å¿ èŠãããŸããããŸããéåžžã®è¢«å®³ãåããŠããªã人ã ã«çŠç¹ãåœãŠãŠããã®ãã©ã¹ããDNAã圌ãã®å¹¹çްèã®ã²ãã ã«çµ±åãããŠãããã©ããã調ã¹ãããšãã§ããŸããããã¯èšŒæ ãæ®ãã®ã§ãããã®ç¹ã«çŠç¹ãåœãŠãŠããçç±ã®1ã€ã¯ãä»ã®å€ãã®æ³åäžã®è¢«å®³ãšã¯ç°ãªãããã§ããããã¯æ¬åœã«èšŒæã§ããªããã®ã§ããã¿ã€ãã³ã°ããçããããšæãããšã¯ã§ããŸãããæ¬åœã«èšŒæããããšã¯ã§ããŸããããã®ç¹ã¯ã蚌æ ãæ®ããã蚌æã§ããŸããããããŸããïŒè¢«å®³ãåãã人ã ã®å¹¹çްèãããããèŠã€ããããšãã§ããŸããããã¯ãä»ã¯äº¡ããªã£ã人ã®äœå ã§ç¹å®ã®ã¿ã€ãã®éãèŠã€ããã®ãšåãã§ãããããåå ã ãšèããã®ã¯ããªã劥åœã§ãã
æ¥çš®è ã®çްèã調ã¹ãã¹ãã蚌æ ã¯æ®ã£ãŠããã
æã ãã€ãŸãçããã¯ãFDAã«å¯ŸããŠãPfizerã«ããŒã¹ã¿ãŒãä»åŸã®ã¯ã¯ãã³ã®ããŒãžã§ã³ããDNAãåãé€ãããšã匷å¶ããããèŠæ±ããã¹ãã§ããç§ã¯ãã®ãã©ãããã©ãŒã ã®å€§ãã¡ã³ãªãã§ããããã¯ããæ²»çã®å¯èœæ§ãç§ããŠãããšæããŸãããã®ãã©ãããã©ãŒã ã¯é©åœçã ãšæ¬åœã«ä¿¡ããŠããŸãããããŠãããªãã®äžçã®éã«ãããªãã®ç¬èªã®ããã«å¯ŸããmRNAã¯ã¯ãã³ãããã§ãããããããã圌ãã¯ãã®åé¡ã解決ããå¿ èŠããããŸãã
ä»ã®éºäŒå補å€ã®éçºã®åã«ãDNAåé¡ã解決ãã¹ãã
çŸæç¹ã§ã¯ãçŸç¶ãç¶æããããšã«ãã財æ¿çã¡ãªãããããŸãã«ã倧ããããããããåãé€ãããã«ã¯äœããã®å¥šå±ãå¿ èŠã ãšæããŸãããã®DNAãååšããããšãèš±ããèŠå¶ã§ããå®éã«ã¯ããã®éãèŠå¶ã®éçãè¶ ããŠãããšã¯æããŸãããäžéšã®ãããã§ã¯ãè¶ ããŠãããããããŸãããç§ã調ã¹ã2ã€ã®ãããã§ã¯ã1ã€ã¯éçããããã«äžåãããã1ã€ã¯éçããããã«è¶ ããŠããŸããããã¹ãã³ã®ååã¯ä»ã®ããããããªã調æ»ããŸããããäžéšã«éåžžã«é«ããã®ãšéåžžã«äœããã®ããããŸãããã¯ã¯ãã³ã«èš±å¯ãããDNAã®éã«å¯ŸããèŠå¶ã®ãããå€ããããšããäºå®ã¯ãç§ãã¡ãçµã¿æãã¿ã³ãã¯è³ªãæ»æ» ãããŠã€ã«ã¹ãCHO现èã§çç£ããã匱æ¯åãŠã€ã«ã¹ã®ãããªã¯ã¯ãã³ã«ã€ããŠè©±ããŠããæä»£ã®åæ®ã§ãã
ããã«å«ãŸããŠãããããããªãDNAã¯è£žã®DNAã§ãã¯ã¯ãã³ã«å°ãå«ãŸãããããããŸãããããã¯åé¡ã§ã¯ãããŸããããªããªã裞ã®DNAã¯ã¯ã¯ãã³æ¥çš®çŽåŸã«ããã«åè§£ããã现èå ã«å ¥ãããã®å®éã®ã¡ã«ããºã ã¯ãããŸããã圌ãã¯èŠå¶ã®éçãäžé©åã«ãã®æ°ããçš®é¡ã®ã¯ã¯ãã³ã«é©çšããŸãããããã§ã¯ããã¹ãŠããã®è質ããç²åã«å ãŸããŠããŸããããã¯åºæ¬çã«ã¯åæãŠã€ã«ã¹ã«å ãŸããŠããããã®å 容ã现èã«æŸåºããããšãã§ããŸããã§ããããç§ã¯ããã¯ãã³ãã³ã®ååã ãšèããŠããŸããç§ã¯ããã«æªæããã£ããšã¯æããŸãããããã¯ãã æããªèŠèœãšãã®äžçš®ã ã£ããšæããŸããã解決ã«ã¯æéããããã§ãããããªããªãã財æ¿çãªã€ã³ã»ã³ãã£ãã®å€§ããããåé¡ãé ãããããæ¿èªãã人ã ã®ãã£ãªã¢ã«ãšã£ãŠããããã¯äœãåé¡ããªããšããããšã«ãããããã§ãã
人ã ã«ããã倧äžå€«ã§ããããšã蚌æããããã«ã¯ãããããã®å¥šå±ãå¿ èŠã§ããããããç§ã¯ãããæ°ããçš®é¡ã®ã¯ã¯ãã³ã«å¯Ÿããå€ãèŠå¶ã®äžé©åãªé©çšã ãšåºãä¿¡ããŠããŸãããããŠèª°ããããã§ããããïŒãããããããç§ãã¡ã¯ããããã®äººã ã調ã¹ãŠã確ãã«ãããåé¡ã§ã¯ãªãããšã確èªãããããããŸããããããŠããã蚌æããã°ãããã¯å ¬å ±ã®å©çã«ãªãã§ãããã
ééçãªå©çãåãã人ã¯åé¡ãªããšãããã ãããã
å€ãã®æ¥çš®è ã調ã¹ãŠåé¡ã®æç¡ã蚌æããã°ãå ¬å ±ã®å©çãšãªãã
確èªïŒ æ¥æ¬äººç§åŠè ã«ããèŠéïŒå¯Ÿè«ïŒ
è¬èŸïŒtonakaiãããficcãããžïŒ
â tonakaiãã
 ã XïŒæ§TwitterïŒã¢ã«ãŠã³ãïŒ@tonakai79780674 ã
ãæ¥æ¬èªèš³æ
å ±ã®ãæäŸããªãã³ã«ãäžå¯§ãªã¬ãã¥ãŒããèª ã«ããããšãããããŸããã
â ficcãã
 ã XïŒæ§TwitterïŒã¢ã«ãŠã³ãïŒ@ficc_ystk ã
ãæŽ»ååã®åŒã³ããããªãã³ã«ãã³ã©ãå®çŸãžã®æ¶ãæ©ããèª ã«ããããšãããããŸããã
æåèµ·ãããçµããŠ
èŽããããªã£ãæ²ã¯ã»ã»ã»
ãå€ã®çµãã®ããŒã¢ããŒã
ç眮浩äº
â 倢ãããããã ã©ããéã£ãŠããã©
ãããåãšåã®ããŒã¢ã㌠â
DNAãšRNAã¯çåœã®ç¥ç§
ããã¯ãŸãã§çŸããããŒã¢ããŒ
åãç¶ãããèžè¡ã«æåããŠããã
ãã®å¥è·¡ãããã€ãŸã§ããã£ãšå¿ããã«ã
以äž